Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Terhaag

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Die Pharmazie|January 1, 1976
[Antiarrhythmic, cardiovascular and toxic actions of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethlenediamine (Falirytmin) as compared to propranolol, quinidine and ajmaline]B Terhaag, W Förster
Zeitschrift Fur Arztliche Fortbildung|January 1, 1984
[Unwanted and toxic drug effects]G W Dominok, B Terhaag
Die Pharmazie|December 1, 1991
[In vitro interactions of talinolol with propranolol and salazosulfapyridine]R Oertel, B Terhaag, K Richter
Farmakologiia I Toksikologiia|July 1, 1987
[Pharmacokinetics of Cordanum]B Terhaag, K Richter, H Pötter
International Journal of Clinical Pharmacology and Biopharmacy|December 1, 1978
Concentration behavior of carbamazepine in bile and plasma of manB Terhaag, K Richter, H Diettrich
Die Pharmazie|January 1, 1992
[The pharmacokinetic behavior of AWD 26-06 in humans following single and multiple administration]B Terhaag, K Richter, K Feller
Die Pharmazie|August 1, 1983
[Pharmacokinetics of talinolol (Cordanum) in man after oral administration]B Terhaag, K Richter, H Pötter
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1988
[Clinico-pharmacologic studies with a M1 receptor antagonist (substance AWD 26-06) in a phase I clinical trial]B Terhaag, T Gramatté, K Feller
Die Pharmazie|November 1, 1985
[The analysis of the compound X50 in human serum]K Richter, G le Petit, B Terhaag
Clinical Pharmacology and Therapeutics|May 1, 1996
Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humansT Gramatté, R Oertel, B Terhaag, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Die Pharmazie|January 1, 1976
[Antiarrhythmic, cardiovascular and toxic actions of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethlenediamine (Falirytmin) as compared to propranolol, quinidine and ajmaline]B Terhaag, W Förster
Zeitschrift Fur Arztliche Fortbildung|January 1, 1984
[Unwanted and toxic drug effects]G W Dominok, B Terhaag
Die Pharmazie|December 1, 1991
[In vitro interactions of talinolol with propranolol and salazosulfapyridine]R Oertel, B Terhaag, K Richter
Farmakologiia I Toksikologiia|July 1, 1987
[Pharmacokinetics of Cordanum]B Terhaag, K Richter, H Pötter
International Journal of Clinical Pharmacology and Biopharmacy|December 1, 1978
Concentration behavior of carbamazepine in bile and plasma of manB Terhaag, K Richter, H Diettrich
Die Pharmazie|January 1, 1992
[The pharmacokinetic behavior of AWD 26-06 in humans following single and multiple administration]B Terhaag, K Richter, K Feller
Die Pharmazie|August 1, 1983
[Pharmacokinetics of talinolol (Cordanum) in man after oral administration]B Terhaag, K Richter, H Pötter
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1988
[Clinico-pharmacologic studies with a M1 receptor antagonist (substance AWD 26-06) in a phase I clinical trial]B Terhaag, T Gramatté, K Feller
Die Pharmazie|November 1, 1985
[The analysis of the compound X50 in human serum]K Richter, G le Petit, B Terhaag
Clinical Pharmacology and Therapeutics|May 1, 1996
Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humansT Gramatté, R Oertel, B Terhaag, et al.
Pageof 6